SCHEMBL27768

SCHEMBL27768

O=C(O)CCCC(=O)C(=O)O

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 2/20 0.69
EGLN1 Q9GZT9 2/20 0.67
MAPK1 P28482 1/20 0.67
SLC13A3 Q8WWT9 1/20 0.67
OR51E2 Q9H255 1/20 0.67
LMNA P02545 4/20 0.59
TSHR P16473 4/20 0.56
NFKB1 P19838 2/20 0.56
PMP22 Q01453 1/20 0.56
CAMK2A Q9UQM7 1/20 0.50
HDAC11 Q96DB2 2/20 0.48
GABRR3 A8MPY1 1/20 0.48
GABRP O00591 1/20 0.48
GABRD O14764 1/20 0.48
HDAC3 O15379 1/20 0.48
GABBR2 O75899 1/20 0.48
CYP1A2 P05177 1/20 0.48
THRB P10828 1/20 0.48
GABRA1 P14867 1/20 0.48
GABRB1 P18505 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL715450 0.97 SLC22A6 (0.65) SLC22A6EGLN1MAPK1SLC13A3OR51E2
Alpha-Ketoglutaric Acid SCHEMBL27892915 0.94 EGLN1 (0.78) SLC22A6EGLN1MAPK1SLC13A3OR51E2
SCHEMBL259198 0.94 LMNA (0.69) SLC22A6EGLN1MAPK1SLC13A3OR51E2
SCHEMBL14357994 0.94 LMNA (0.69) SLC22A6EGLN1MAPK1SLC13A3OR51E2
Urea SCHEMBL29106847 0.92 SLC22A6 (0.58) SLC22A6EGLN1MAPK1SLC13A3OR51E2
SCHEMBL2993356 0.91 TSHR (0.71) SLC22A6EGLN1MAPK1SLC13A3OR51E2
SCHEMBL9794734 0.91 TSHR (0.71) SLC22A6EGLN1MAPK1SLC13A3OR51E2
SCHEMBL20537125 0.91 TSHR (0.71) SLC22A6EGLN1MAPK1SLC13A3OR51E2
SCHEMBL15052528 0.91 LMNA (0.65) SLC22A6EGLN1MAPK1SLC13A3OR51E2
SCHEMBL2780784 0.91 TSHR (0.71) SLC22A6EGLN1MAPK1SLC13A3OR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747627-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS Matterworks Inc (US) 2026-05-27 EP claimed
EP-3869192-B1 METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE HUMAN METABOLOMICS INST INC (CN) 2026-05-13 EP claimed
US-12566228-B2 Temperature cycling method for hyperpolarization of target molecules and contrast agents using parahydrogen NORTH CAROLINA STATE UNIVERSITY (US) 2026-03-03 US claimed
US-20260048155-A1 BIOCOMPATIBLE PARAHYDROGEN HYPERPOLARIZED SOLUTIONS BY PRECIPITATION AND RE-DISSOLUTION UNIV NORTH CAROLINA STATE (US) 2026-02-19 US claimed
EP-4679086-A1 BIOMARKER AND USE THEREOF MEIJI CO., LTD (JP) 2026-01-14 EP claimed
US-12435294-B2 Prevention of the oxidation of perfumery raw materials and food raw materials FIRMENICH SA (CH) 2025-10-07 US claimed
US-20250271524-A1 METHODS FOR PROTON-ONLY DETECTION OF HYPERPOLARIZED HETERONUCLEAR SINGLET STATES WAYNE STATE UNIVERSITY 2025-08-28 US claimed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US claimed
EP-4544061-A1 MICROORGANISMS AND METHODS FOR THE CONTINUOUS CO-PRODUCTION OF TANDEM REPEAT PROTEINS AND CHEMICAL PRODUCTS FROM C1-SUBSTRATES Lanzatech, Inc. (US) 2025-04-30 EP claimed
EP-4544062-A1 MICROORGANISMS AND METHODS FOR THE CONTINUOUS CO-PRODUCTION OF HIGH-VALUE, SPECIALIZED PROTEINS AND CHEMICAL PRODUCTS FROM C1-SUBSTRATES Lanzatech, Inc. (US) 2025-04-30 EP claimed
WO-2005052575-A1 MOLECULAR MARKERS OF OXIDATIVE STRESS PFIZER LIMITED (GB) 2005-06-09 WO claimed
EP-1524989-A2 METHOD AND COMPOSITION FOR PROTECTING NEURONAL TISSUE FROM DAMAGE INDUCED BY ELEVATED GLUTAMATE LEVELS YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) 2005-04-27 EP claimed
WO-2004012762-A2 METHOD AND COMPOSITION FOR PROTECTING NEURONAL TISSUE FROM DAMAGE INDUCED BY ELEVATED GLUTAMATE LEVELS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2004-02-12 WO claimed
EP-1041154-B1 Process for the preparation of 5-aminolevulinic acid COSMO RES INST (JP) 2003-03-12 EP claimed
US-20020155192-A1 Yeast transport isoforms MEDICAL RESEARCH COUNCIL (GB) 2002-10-24 US claimed
WO-2002010395-A1 ISOFORMS OF AN OXODICARBOXYLATES TRANSPORTER OF S. CEREVISIAE MEDICAL RESEARCH COUNCIL (GB) 2002-02-07 WO claimed
EP-1041154-A1 5-Aminolevulinic acid producing microorganism and process for producing 5-aminolevulinic acid COSMO RESEARCH INSTITUTE (JP) 2000-10-04 EP claimed
US-5763235-A PHOTOSYNTHETIC BACTERIUM WHICH PRODUCES 5-AMINOLEVULINIC ACID WITHOUT LIGHT IRRADIATION COSMO RESEARCH INSTITUTE (JP) 1998-06-09 US claimed
EP-0718405-A2 5-Aminolevulinic acid producing microorganism, and process for producing it COSMO RESEARCH INSTITUTE (JP) 1996-06-26 EP claimed
US-4931509-A EPOXY-CONTAINING MONOMER; EXCELLENT VULCANIZING WITH UREAS, QUATERNARY AMMONIUM AND PHOSPHONIUM SALTS AND POLYCARBOXYLIC ACIDS OR ANHYDRIDES NIPPON ZEON CO., LTD. (JP) 1990-06-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048155-A1 BIOCOMPATIBLE PARAHYDROGEN HYPERPOLARIZED SOLUTIONS BY PRECIPITATION AND RE-DISSOLUTION HNRNPR, SIGMAR1, MAP2K1 SLC22A6 1086/4885EGLN1 1749/4885MAPK1 200/4885
US-12435294-B2 Prevention of the oxidation of perfumery raw materials and food raw materials CUTA, MPO, GPX4 SLC22A6 3941/4885EGLN1 1050/4885MAPK1 2336/4885
US-12566228-B2 Temperature cycling method for hyperpolarization of target molecules and contrast agents using parahydrogen PDK1, MPC2, PC SLC22A6 689/4885EGLN1 382/4885MAPK1 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.